lifestyle.thepointnews.com

Author: Teva Pharmaceutical Industries Ltd

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults

February 20, 2026
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

February 18, 2026
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

February 7, 2026
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

January 27, 2026